How will the credit crunch affect R&D strategy in the pharma industry?

17 November 2008

In a constantly evolving economic landscape, companies of all shapes and sizes are adapting their product development strategies to the constraints of the credit crunch and the pharmaceutical industry is no exception. R&D is increasingly focusing on drugs that will provide maximum sales returns and sector analysts at Global Insight have examined what this will mean for the future of niche medicine, and where new opportunities for innovation will be created.

In its wake, are a growing number of companies that are facing an uncertain future. Their main fear is not having enough access to credit to pursue business development. Drugmakers operating within the brand-name sector are by no means exempt from these fears, although pharmaceutical and biotechnology firms are each facing their own unique challenges.

Within the pharmaceutical industry, it seems that bigger is currently better when it comes to surviving the financial crisis. As a rule of thumb, Big Pharma is not as reliant on cheap credit for funding as other businesses. This has been demonstrated through several recent large-scale acquisitions. For example, the $8.8-billion takeover of US firm Millennium Pharmaceuticals by Japanese drug giant Takeda was financed as an all-cash tender offer, with Takeda's only fundraising move being the acquisition of 1.24% of its own shares. The cash-rich nature of Big Pharma players puts them at a decided advantage when it comes to seeking growth through acquisitions, and also helps provide continued funding for R&D.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight